Swiss Biotech – Industry news, events, directory, Swiss Biotech Association

May 4-5, 2026

The power of international collaboration

Get the insight

Swiss Biotech Report 2025

In print & digitally

The leading compedium of Swiss Biotech

How did we fare in 2024?

Our association in facts and figures

Become a Member

Loads of reasons to join

Invest in Swiss biotechs

Discover investment and partnering opportunities

Talent meets opportunities

Become part of the thriving community

Create lasting business ties

Connect with the Swiss biotech ecosystem

Get the insight

Swiss Biotech Report 2025

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriers Publication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to inte
January 16, 2026

Xenometrix has launched the Rapid Micronucleus MoA (Mode of Action) Telomere Centromere Kit, a next-generation assay that accelerates and improves mechanistic genotoxicity analysis.
January 15, 2026

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Est
January 12, 2026

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroi
January 6, 2026